Abstract Title:

Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial.

Abstract Source:

Eur Ann Allergy Clin Immunol. 2003 Jun;35(6):212-6. PMID: 12872680

Abstract Author(s):

Se Haeng Cho, Young Bok Jung, Sang Cheol Seong, Hyung Bin Park, Ki Yong Byun, Dong Chul Lee, Eun Kyoo Song, Jung Hwan Son

Article Affiliation:

Yonsei Medical Clinic, Seoul, Korea.

Abstract:

OBJECTIVE: To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis.

METHODS: In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects.

RESULTS: Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial.

CONCLUSION: Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.